1JNJ logo

Johnson & JohnsonBIT:1JNJ Stock Report

Market Cap €346.3b
Share Price
€143.72
My Fair Value
AN
AnalystConsensusTarget
€149
3.5% undervalued intrinsic discount
1Y-2.2%
7D2.4%
Portfolio Value
View

Johnson & Johnson

BIT:1JNJ Stock Report

Market Cap: €346.3b

1JNJ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Johnson & Johnson Competitors

Price History & Performance

Summary of share price highs, lows and changes for Johnson & Johnson
Historical stock prices
Current Share PriceUS$143.72
52 Week HighUS$156.80
52 Week LowUS$127.72
Beta0.40
1 Month Change10.23%
3 Month Change6.36%
1 Year Change-2.24%
3 Year Change-16.37%
5 Year Change15.35%
Change since IPO16.20%

Recent News & Updates

Recent updates

Shareholder Returns

1JNJIT PharmaceuticalsIT Market
7D2.4%1.1%2.1%
1Y-2.2%-19.3%17.5%

Return vs Industry: 1JNJ exceeded the Italian Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: 1JNJ underperformed the Italian Market which returned 17.5% over the past year.

Price Volatility

Is 1JNJ's price volatile compared to industry and market?
1JNJ volatility
1JNJ Average Weekly Movement2.9%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement4.2%
10% most volatile stocks in IT Market8.1%
10% least volatile stocks in IT Market2.6%

Stable Share Price: 1JNJ has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1JNJ's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886138,100Joaquin Duatowww.jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
1JNJ fundamental statistics
Market cap€346.33b
Earnings (TTM)€19.29b
Revenue (TTM)€77.14b
18.0x
P/E Ratio
4.5x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1JNJ income statement (TTM)
RevenueUS$90.63b
Cost of RevenueUS$28.64b
Gross ProfitUS$61.99b
Other ExpensesUS$39.33b
EarningsUS$22.66b

Last Reported Earnings

Jun 29, 2025

Next Earnings Date

Oct 14, 2025

Earnings per share (EPS)9.42
Gross Margin68.40%
Net Profit Margin25.00%
Debt/Equity Ratio66.9%

How did 1JNJ perform over the long term?

See historical performance and comparison

Dividends

3.1%
Current Dividend Yield
53%
Payout Ratio

Does 1JNJ pay a reliable dividends?

See 1JNJ dividend history and benchmarks
When do you need to buy 1JNJ by to receive an upcoming dividend?
Johnson & Johnson dividend dates
Ex Dividend DateAug 25 2025
Dividend Pay DateSep 09 2025
Days until Ex dividend31 days
Days until Dividend pay date46 days

Does 1JNJ pay a reliable dividends?

See 1JNJ dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/24 18:57
End of Day Share Price 2025/07/24 00:00
Earnings2025/06/29
Annual Earnings2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Johnson & Johnson is covered by 60 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Charles ButlerBarclays
Matthew MiksicBarclays